What is KROS stock price today?

KROS (Keros Therapeutics Inc) stock is trading at $11.71 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is KROS stock going up or down today?

KROS stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy KROS stock now?

The decision to buy KROS depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is KROS a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for KROS based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is KROS stock overvalued or undervalued?

KROS currently trades at a P/E ratio of 5.02, which may suggest attractive valuation. Our DCF calculator provides intrinsic value estimates to help determine if KROS is fairly priced.

What is KROS's P/E ratio?

KROS has a price-to-earnings (P/E) ratio of 5.02, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is KROS's market cap?

KROS (Keros Therapeutics Inc) has a market capitalization of $0.35 billion, making it a small-cap stock.

What is KROS's price to book ratio?

KROS trades at a price-to-book (P/B) ratio of 0.75, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does KROS pay dividends?

KROS does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is KROS's dividend yield?

KROS does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is KROS stock a good long-term investment?

KROS's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is KROS's revenue growth rate?

KROS has shown revenue growth of -0.9% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, KROS is profitable with a profit margin of 0.4%. This indicates the company generates 0.4 cents of profit for every dollar of revenue.

What are the risks of investing in KROS?

Key risks for KROS include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does KROS compare to its competitors?

Compare KROS to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize KROS's performance and positioning.

What is KROS's stock price target for 2026?

Our AI model provides price targets for KROS based on fundamental analysis: Bull case $15.22 (+30%), Base case $13.47 (+15%), Bear case $10.54 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about KROS?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for KROS. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is KROS's next earnings report?

KROS reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

KROS - Keros Therapeutics Inc

NYSE * Health Care * Biotechnology

$11.71

+$0.16 (+1.39%)

About Keros Therapeutics Inc

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

KROS Key Statistics

Market Cap

$351.88M

P/E Ratio

5.02

P/B Ratio

0.75

EPS

$2.30

Revenue Growth

-0.9%

Profit Margin

0.4%

Employees

How KROS Compares to Peers

KROS has the lowest P/E ratio in Biotechnology, suggesting it may be the most undervalued

KROS has the highest profit margins in Biotechnology

KROS is the smallest among peers, which may offer higher growth potential

P/E Rank

of 6

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
KROS(This stock)	$351.88M	5.0	-1%	0.4%	-
AMGNAmgen Inc	$189.19B	24.7	0%	0.2%	vs AMGN
GILDGilead Sciences	$174.33B	20.7	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.01B	29.0	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.87B	18.2	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.26B	20.4	-0%	0.1%	vs BIIB

Keros Therapeutics Inc Company Information

Headquarters: Massachusetts; U.S.A
Website: www.kerostx.com
Sector: Health Care
Industry: Biotechnology

KROS - Keros Therapeutics Inc

About Keros Therapeutics Inc

KROS Key Statistics

How KROS Compares to Peers

Keros Therapeutics Inc Company Information

KROS Lician Score

KROS Financial Snowflake

Upcoming Events for KROS